Researchers find biomarker for early onset GVHD after transplant

01/8/2010 | Science News

Researchers have discovered that a protein called elafin showed up in greater concentrations among bone marrow transplant patients who exhibited a skin rash after the procedure and developed graft-versus-host disease later on compared with those who did not develop the disease. The new protein biomarker could help determine whether skin rash is a sign of early developing GVHD after bone marrow transplant, as well as identify the patients who need more aggressive treatment, the researchers said.

View Full Article in:

Science News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX